Biologics Outsourcing Market 2024 | Size, Top Trends, Growth, Share, Key Drivers | AbbVie Inc., Thermo Fisher Scientific Inc., Boehringer Ingelheim GmbH, Lonza Group Ag, Catalent Inc.

The Biologics Outsourcing Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Biologics Outsourcing Market:
https://www.thebusinessresearchcompany.com/report/biologics-outsourcing-global-market-report

According to The Business Research Company’s Biologics Outsourcing Global Market Report 2024, The biologics outsourcing market size has grown rapidly in recent years. It will grow from $17.74 billion in 2023 to $20.33 billion in 2024 at a compound annual growth rate (CAGR) of 14.6%. The growth in the historic period can be attributed to increasing r&d costs, regulatory pressure, demand for specialized expertise, globalization.

The biologics outsourcing market size is expected to see rapid growth in the next few years. It will grow to $33.29 billion in 2028 at a compound annual growth rate (CAGR) of 13.1%. The growth in the forecast period can be attributed to emerging markets’ growth, personalized medicine, strategic alliances, biological drug patent expirations. Major trends in the forecast period include advancements in technology, increased outsourcing complexity, biosimilars market expansion, data analytics integration, supply chain resilience.

The rising number of cancer cases is expected to propel the growth of the biologics outsourcing market going forward. Cancer is a broad category of illnesses that can develop in nearly any organ or tissue in the body when aberrant cells proliferate uncontrollably, cross their usual boundaries, and either spread to other organs or invade neighboring body parts. Biologics outsourcing plays a significant role in cancer cases by providing specialized expertise, resources, and infrastructure for the development, manufacturing, and clinical supply of biologic therapies, including monoclonal antibodies, immunotherapies, and other targeted biologics that are used for the diagnosis, treatment, and management of various types of cancer. For instance, in January 2023, according to the National Center for Biotechnology Information, a US-based intergovernmental organization, there were 1,958,310 new cancer cases in the United States, and 609,820 cancer deaths are projected to occur in 2023. Further, the number of new cancer cases per year is expected to rise to 29.5 million and the number of cancer-related deaths to 16.4 million by 2040. Therefore, the rising number of cancer cases is driving the growth of the biologics outsourcing market.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=12573&type=smp

The biologics outsourcing market covered in this report is segmented –
1) Biologics Outsourcing Market By Product Type: Antibodies, Recombinant, Vaccines, Protein, Other Products
2) Biologics Outsourcing Market By Source: Human, Microbial, Other Source
3) Biologics Outsourcing Market By Application: Oncology, Cellular and Gene Therapy, Blood And Blood-Related Products Development, Vaccine Development, Stem Cell Research, Other Applications
4) Biologics Outsourcing Market By End User: Pharmaceutical Industries, Biotechnology Industries, Contract Development And Manufacturing Organization(CDMO)

Top Major Players

AbbVie Inc.

Thermo Fisher Scientific Inc

Boehringer Ingelheim GmbH

Lonza Group Ag

Catalent Inc.

Developments in biologics are a key trend gaining popularity in the biologics outsourcing market. Major companies operating in the biologics outsourcing market are adopting new technologies to sustain their position in the market. For instance, in February 2022, Abzena, a US-based contract development and manufacturing organization (CDMO), Alira Health, a US-based healthcare firm, and Oncodesign, a France-based biopharmaceutical company, launched DRIVE-Biologics, a consortium designed for biologic drug discovery and development programs. This provides integrated solutions with specialist services, from biological discovery to clinical and commercial manufacturing. This partnership, which combines industry leadership in fields such as design and developability, proof of concept in preclinical pharmacology and pharmaco-imaging, toxicology, and clinical design through commercial manufacturing, would streamline information sharing and program deliverables to help de-risk biologics development. Additionally, partners would have access to expertise at all drug discovery and development stages, including design, preclinical, clinical, and CMC (chemistry, manufacturing, and control).

The biologics outsourcing market report table of contents includes:

1. Executive Summary

2. Biologics Outsourcing Market Characteristics

3. Biologics Outsourcing Market Trends And Strategies

4. Biologics Outsourcing Market – Macro Economic Scenario

5. Global Biologics Outsourcing Market Size and Growth

…….

32. Global Biologics Outsourcing Market Competitive Benchmarking

33. Global Biologics Outsourcing Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Biologics Outsourcing Market

35. Biologics Outsourcing Market Future Outlook and Potential Analysis

36. Appendix